AZ and Roche have agreed to collaborate on the development of a diagnostic test for lung cancer.
AstraZeneca (AZ) and Roche have announced they are joining forces to develop a diagnostic test to help identify the most suitable treatments for patients with non-small cell lung cancer (NSCLC).
The test will serve as a companion to support AZ’s investigational compound, AZD9291, and offer a more convenient method for determining the specific mutations of the cancer and therefore the most suitable treatment.
As this form of disease accounts for between 80 and 85% of lung cancer cases, the test will ensure many more people get access to the treatment best suited to their tumour, hopefully offering better outcomes for the patient.
Mondher Mahjoubi, senior vice-president for global product strategy for oncology at AZ, said: “Understanding the nature of each individual’s tumour and therefore which medicine is most likely to benefit them is vital if we are to transform the way cancer patients are diagnosed and treated.”